Consensus DiaSorin S.p.A.

Equities

DIA

IT0003492391

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-04-19 am EDT			After market 03:59:58 pm
91.18 ^EUR	+1.79%		90.98	-0.22%

04:08pm	Marble Bar Asset Management cuts short on OVS.	AN
Apr. 18	Marshall Wace moves on Leonardo and OVS.	AN

Evolution of the average Target Price on DiaSorin S.p.A.

Price target over the last 5 years

History of analyst recommendation changes

29a4b2c89.aIrEYB1t31wrzEucZSpge98Q7A_Q4m9p9Vlg3hD4cqk.P7n3GU8fvgpRpC3NIHpXSJVJmz2fjSsFkRsRk1-REfor87MIRR2JZHyfGg~af0ead7acac1225c16d9500508d64e35

Analyst Recommendations on DiaSorin S.p.A.

Marble Bar Asset Management cuts short on OVS.	10:08am	AN
Marshall Wace moves on Leonardo and OVS.	Apr. 18	AN
Millennium International cuts short on DiaSorin	Apr. 09	AN
JPMorgan revises three bearish positions.	Apr. 02	AN
BlackRock and Capital Fund exceed 0.5 percent on TIM	Mar. 21	AN
JPMorgan initiates short on De Nora Industries.	Mar. 20	AN
Balyasny and Millennium raise short on DiaSorin	Mar. 19	AN
Marshall Wace moves on Ferragamo and Piaggio.	Mar. 18	AN
DIASORIN : Invest Securities lowers its target price	Mar. 18	CF
DIASORIN : Profitability guidance miss; dreams inching towards reality	Mar. 18
DIASORIN : Incorporating some caution	Feb. 05
DIASORIN : Q3 profitability miss; Immunodiagnostics momentum continues; guidance unchanged	Nov. 06
Chinese headwinds could be more severe than expected	23-09-22
DIASORIN : Taking on board the near-term difficulties	23-08-16
DIASORIN : Despite a soft Q2, guidance was unchanged	23-07-28
DIASORIN : Incorporating medium-term hiccups; but re-rating potential remains intact	23-05-19
DIASORIN : Mixed Q1; guidance unchanged	23-05-10
DIASORIN : Soft 2022 (end) + disappointing guidance; patience warranted	23-03-28
Berenberg European Conference	22-12-04	FA
DIASORIN : A decent Q3 + better guidance but markets were spooked	22-10-28
DIASORIN : Healthy Q2 and H1; resulting in consecutive guidance upgrade	22-08-04
DIASORIN : Strong Q1 prompts guidance upgrade	22-05-10
Berenberg Diagnostics Conference	22-05-09	FA
DIASORIN : Healthy 2021 performance; 2022 guidance being reiterated	22-03-20
DIASORIN : Mid-to-long-term ambitions overshadowed by near-term headwinds	21-12-20